epistaxis, hematuria, subcutaneous hematoma, and gastrointestinal and gingival bleeding. He continues to take Factor X concentrate prophylactically. All the patients are currently healthy and regularly follow up in our center. Results Conclusion: Since there is no FX concentrate in our country yet, FFP is used. Patients should be treated with the appropriate FX preparation and a prophylactic approach should be applied in necessary patients.

Table. Patient Characteristics and Diagnostic Laboratory Results

Patient No	Age at analysis	Gender	FX %		PTT sec 22.5-31.3	_	Treatment
1. 2. 3. 4. 5.	41 25 18 34 1	F F F M	0.2 12.3 0.8 34.4 1	60.4 31.5 37 13.9 180	64.1 57.9 19.3 28.3 138	11 0 11 15 10	FFP, ES, PCC Not need FFP, ES, PCC FFP FFP, FXC, PCC

*- International Society for Thrombosis and Hemostasis/Scientific and Standardization Committee Bleeding Assessment Tool (ISTH-BAT), FFP- fresh frozen plasma, ES- erythrocyte suspension, PCC-prothrombin complex concentrate, FXC- Factor X concentrate, F-female, M-Male

https://doi.org/10.1016/j.htct.2023.09.059

Adult Hematology Abstract Categories

Lymphoma PP 10

REACTION OF THE CIRCULATING
REGULATORY T CELLS AFTER
CHEMORADIATION THERAPY OF HODGKIN
LYMPHOMA

Tatiana Mushkarina ¹, Evgenija Kuzmina ¹, Tatiana Bogatyreva ¹, Ludmila Grivtsova ¹

¹ A. Tsyb Medical Radiological Research Centre MRRC

Objective: Purpose of the research is to determine the reaction of regulatory T cells after chemoradiation therapy of Hodgkin lymphoma. Methodology: 29 samples of peripheral blood of patients with Hodgkin lymphoma (before treatment - 10; after chemotherapy - 9; after consolidation radiotherapy -10). Chemotherapy was carried out according to the following schemes: ABVD, BEACOPP with the addition of 1-2 courses of CVPP or COPP. The subsequent consolidation of radiation therapy was accomplished to a dose of 20-24 Gy. Treg-cells were identified by phenotype CD45+CD4+CD25+CD127-. Control group consisted of 40 practically healthy people. The group data were compared using the Mann-Whitney U test. Results: At the onset of Hodgkin lymphoma the percentage and absolute count of regulatory T cells corresponded to normal values (5.19%/0.036*109 cells/l - Hodgkin lymphoma vs $3.69\%/0.031*10^9$ cells/l - control level, p>0.05). After chemotherapy the percentage of regulatory T cells increased to 9.09%, p<0.05; the absolute count remained at the same level (0.037*109 cells/l, p>0.05). After consolidation of radiation therapy the percentage of regulatory T cells was determined

at the level of 9.19%, p>0.05. The decrease of absolute count of regulatory T cells was statistically significant difference and was near 0.019*10⁹ cells/l. **Conclusion**: There is a relative redistribution of cells within a subpopulation of activated CD4+CD25+T cells towards an increase in the level of regulatory T cells after chemotherapy of Hodgkin lymphoma. The subsequent radiotherapy consolidation at a dose of 20-24 Gy continued to increase the sensitivity of regulatory T cells to the radiation component of chemoradiation therapy.

https://doi.org/10.1016/j.htct.2023.09.060

PP 11

CUTANEOUS RICHTER TRANSFORMATION IN THE 16TH YEAR OF FOLLICULAR LYMPHOMA DIAGNOSIS

Ulviyya Hasanzade ¹, Yunus Catma ¹, Nur Seda Ibili Cetinkaya ¹, Beyza Oluk ¹, Simge Erdem ¹, Cem Hacialioglu ¹, Ahmet Oguz Celik ², Musa Falay ², Sevgi Kalayoglu Besisik ¹

- ¹ Istanbul University İstanbul Medical Faculty, Department Of Internal Medicine Division Of Hematology
- ² İstanbul University Istanbul Medical Faculty, Department Of İnternal Medicine

Case report: Richter transformation may develop in lymph nodes or rarely extranodally. A 70-year-old male with an exhausted appearance had a large malodorous wound progressing to necrosis on the left chest wall. He received two treatment lines 5 years apart for follicular lymphoma and was in remission. Histological evaluation showed triple hit diffuse large B cell lymphoma. PET-CT showed localized cutaneous and lymph node involvement. Two treatment lines did not control the disease. He passed on progression.

https://doi.org/10.1016/j.htct.2023.09.061

PP 12

AUTOLOGOUS HEMATOPOIETC CELL TRANSPLANTATION (HCT) FOR HODGKIN LYMPHOMA, REAL WORLD EXPERIENCE OF A SINGLE CENTER EXPERIENCE

Carmino De Souza¹, Marcos Colella¹, Eliana Miranda¹, Lorena Bedotti¹, Afonso Vigorito^{1,2}

- ¹ University of Campinas UNICAMP, Hematology and Hemotherapy Center
 ² University of Campinas - UNICAMP, Bone Marrow
- ² University of Campinas UNICAMP, Bone Marrow Transplantation Unit, Hematology and Hemotherapy Center

Objective: Hodgkin's Lymphoma (HL) during the years became a high curable hematology malignant disease.